Effect of sodium diclofenac on the bioavailability of amoxicillin

被引:13
作者
Bergamaschi, CDC
Motta, RHL
Franco, GCN
Cogo, K
Montan, MF
Ambrosano, GMB
Rosalen, PL
Del Fiol, FDS
Groppo, FC
机构
[1] Univ Estadual Campinas, Piracicaba Dent Sch, Dept Pharmacol Anesthesiol & Therapeut, BR-13414903 Piracicaba, SP, Brazil
[2] Sao Leopoldo Dent Sch, Dept Physiol Sci, Campinas, SP, Brazil
[3] Sch Pharm Sorocaba, Dept Pharmacol, Sorocaba, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
amoxicillin; drug interaction; sodium diclofenac; pharmacokinetic parameters; bioavailability;
D O I
10.1016/j.ijantimicag.2006.02.005
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
The aim of this study was to evaluate the effect of sodium diclofenac on the bioavailability of amoxicillin. In this randomised, crossover study with a 1-week washout period, 20 volunteers received a 2 g oral dose of amoxicillin (Amoxil (R)) (Group 1) or a 2 g oral dose of amoxicillin with 100 mg of sodium diclofenac (Voltaren (R)) (Group 2). Blood samples were collected at 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 h following drug administration. High-performance liquid chromatography with ultraviolet detection was used to quantify plasma amoxicillin concentrations. Bioassay (Micrococcus luteus ATCC 9341) was performed to verify them antimicrobial efficacy of amoxicillin in vitro. The pharmacokinetic parameters area under the plasma concentration-time curve (AUC), maximum plasma concentration observed during the 24-h study period (C-max) and renal clearance (CL) were analysed by analysis of variance, and time at which C-max occurred (T-max) and volume of distribution (VD) were analysed by Wilcoxon test (P < 0.05). For Group 1, the mean (standard deviation) AUC(0-24), C-max and T-max values were 3391.8 +/- 1186.7 mu g min/mL, 17.3 +/- 6.5 mu g/mL and 121.5 +/- 20.6 min, respectively; and for Group 2, the values were 2918.4 +/- 1024.8 mu g min/mL, 15.5 +/- 5.8 mu g/mL and 136.5 +/- 30.0 min, respectively. Lower values of AUC and C-max were observed for Group 2 (P < 0.05). CL of amoxicillin increased (P < 0.05) by 18.5% in Group 2, suggesting that sodium diclofenac may interfere with amoxicillin renal excretion. In conclusion, sodium diclofenac can significantly reduce the bioavailability of amoxicillin. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:417 / 422
页数:6
相关论文
共 40 条
[1]
A review of perioperative corticosteroid use in dentoalveolar surgery [J].
Alexander, RE ;
Throndson, RR .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS, 2000, 90 (04) :406-415
[2]
Ammon S, 2000, DRUG METAB DISPOS, V28, P1149
[3]
Annadurai S., 1998, Indian Journal of Experimental Biology, V36, P86
[4]
Baglie S, 2005, INT J CLIN PHARM TH, V43, P350
[5]
Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms [J].
Bantar, C ;
Nicola, F ;
Canigia, LF ;
Arenoso, HJ ;
Soutric, J ;
Montoto, M ;
Blanco, M ;
Smayevsky, J ;
Jasovich, A .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (04) :402-406
[6]
BRUNUSINO A, 1999, EUR B DRUG RES, V7, P5
[7]
AUTOMATED-DETERMINATION OF AMOXYCILLIN IN BIOLOGICAL-FLUIDS BY COLUMN SWITCHING IN ION-PAIR REVERSED-PHASE LIQUID-CHROMATOGRAPHIC SYSTEMS WITH POST-COLUMN DERIVATIZATION [J].
CARLQVIST, J ;
WESTERLUND, D .
JOURNAL OF CHROMATOGRAPHY, 1985, 344 (NOV) :285-296
[8]
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney [J].
Cha, SH ;
Sekine, T ;
Fukushima, J ;
Kanai, Y ;
Kobayashi, Y ;
Goya, T ;
Endou, H .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :1277-1286
[9]
ORAL AMOXICILLIN AS PROPHYLAXIS FOR ENDOCARDITIS - WHAT IS THE OPTIMAL DOSE [J].
DAJANI, AS ;
BAWDON, RE ;
BERRY, MC .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (02) :157-160
[10]
Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine [J].
Damkier, P ;
Hansen, LL ;
Brosen, K .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (06) :829-838